Petros P Sfikakis, Dimitrios Vassilopoulos, Gkikas Katsifis, Georgios Vosvotekas, Theodoros Dimitroulas, Prodromos Sidiropoulos, Periklis Vounotrypidis, Dimitrios P Bogdanos, Athanasios Ι Georgountzos, Andreas G Bounas, Panagiotis Georgiou, Souzana Gazi, Evangelia Kataxaki, Stamatis-Nick Liossis, Evangelos Theodorou, Charalampos Papagoras, Evangelos Theotikos, Panayiotis Vlachoyiannopoulos, Paraskevi V Voulgari, Angeliki Kekki, Nikolaos Antonakopoulos, Dimitrios T Boumpas
To evaluate the effect of the phosphodiesterase 4 inhibitor apremilast in biologic-naïve patients with early peripheral PsA in terms of disease activity, clinical manifestations, patient-perceived outcomes, as well as apremilast's safety profile in routine care settings of Greece. Non-interventional, multicenter, 52-week prospective cohort study, enrolling biologic-naïve patients with early active peripheral PsA who started apremilast after intolerance or inadequate response (within the first 12 months of treatment) to an initial conventional synthetic (cs)DMARD treatment...
March 1, 2023: Rheumatology International